Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracey G Simon

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
JAMA Surgery|October 1, 2015
Association of Model for End-Stage Liver Disease Score and Mortality in Trauma Patients With Chronic Liver DiseaseAllan Peetz, Ali Salim, Reza Askari, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVESAdeel A Butt, Peng Yan, Hector Bonilla, et al.
Digestive Diseases and Sciences|March 1, 2015
Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical OutcomesKara B Johnson, Jessica L Mueller, Tracey G Simon, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulationJonggi Choi, Ana Verma, Vy H Nguyen, et al.
The American Journal of Gastroenterology|May 12, 2026
GLP-1 receptor agonist use and liver-related outcomes in MASLD and type 2 diabetes in the All of Us Research ProgramErik Almazan, Jonggi Choi, Tushar Kamath, et al.
International Journal of Cardiology|June 16, 2018
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibeTracey G Simon, Kathleen E Corey, Christopher P Cannon, et al.
Hepatology Communications|April 13, 2026
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetesJonggi Choi, Gabby Mitchell, Vy H Nguyen, et al.
Clinical and Molecular Hepatology|November 11, 2025
Comparative Risk of Fibrosis Progression with SGLT2 vs. DPP-4 Inhibitors in MASLD and T2DM with Low-to-Intermediate FibrosisJonggi Choi, Daniel Fulop, Vy H Nguyen, et al.
International Journal of Epidemiology|July 15, 2019
Meat intake and risk of hepatocellular carcinoma in two large US prospective cohorts of women and menYanan Ma, Wanshui Yang, Tricia Li, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 18, 2025
GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score MatchingJonggi Choi, Tushar Kamath, Vy H Nguyen, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
JAMA Surgery|October 1, 2015
Association of Model for End-Stage Liver Disease Score and Mortality in Trauma Patients With Chronic Liver DiseaseAllan Peetz, Ali Salim, Reza Askari, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVESAdeel A Butt, Peng Yan, Hector Bonilla, et al.
Digestive Diseases and Sciences|March 1, 2015
Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical OutcomesKara B Johnson, Jessica L Mueller, Tracey G Simon, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulationJonggi Choi, Ana Verma, Vy H Nguyen, et al.
The American Journal of Gastroenterology|May 12, 2026
GLP-1 receptor agonist use and liver-related outcomes in MASLD and type 2 diabetes in the All of Us Research ProgramErik Almazan, Jonggi Choi, Tushar Kamath, et al.
International Journal of Cardiology|June 16, 2018
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibeTracey G Simon, Kathleen E Corey, Christopher P Cannon, et al.
Hepatology Communications|April 13, 2026
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetesJonggi Choi, Gabby Mitchell, Vy H Nguyen, et al.
Clinical and Molecular Hepatology|November 11, 2025
Comparative Risk of Fibrosis Progression with SGLT2 vs. DPP-4 Inhibitors in MASLD and T2DM with Low-to-Intermediate FibrosisJonggi Choi, Daniel Fulop, Vy H Nguyen, et al.
International Journal of Epidemiology|July 15, 2019
Meat intake and risk of hepatocellular carcinoma in two large US prospective cohorts of women and menYanan Ma, Wanshui Yang, Tricia Li, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 18, 2025
GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score MatchingJonggi Choi, Tushar Kamath, Vy H Nguyen, et al.
Pageof 13